CXCL12 G801A polymorphism and cancer risk: An updated meta-analysis.
10.1007/s11596-015-1431-4
- Author:
Dan MENG
1
;
Yin-Xiang WU
;
Vidhi HEERAH
;
Shuang PENG
;
Meng-di CHU
;
Yong-Jian XU
;
Wei-Ning XIONG
;
Shu-Yun XU
Author Information
1. Department of Respiratory and Critical Care Medicine, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, China, sdmd1989@163.com.
- Publication Type:Journal Article
- MeSH:
Asian Continental Ancestry Group;
genetics;
Chemokine CXCL12;
genetics;
European Continental Ancestry Group;
genetics;
Genetic Predisposition to Disease;
Humans;
Neoplasms;
ethnology;
genetics;
pathology;
Odds Ratio;
Polymorphism, Single Nucleotide
- From:
Journal of Huazhong University of Science and Technology (Medical Sciences)
2015;35(3):319-326
- CountryChina
- Language:English
-
Abstract:
Many studies have reported the relationship between CXCL12 G801A polymorphism and cancer risk, with conflicting results. In this study, we tried to clarify the possibility that this polymorphism may increase cancer risk by conducting an updated meta-analysis. PubMed and EMbase were searched for case-control studies regarding the association of the gene polymorphism and cancer risk. Data were extracted and odds ratios (ORs) with 95% confidence intervals (95% CIs) were used to assess the strength of the association. Heterogeneity among articles and publication bias was also assessed. Significantly increased risk for cancer was found (A vs. G: OR=1.26, 95% CI=1.13-1.40, P<0.01; AA+AG vs. GG: OR=1.33, 95% CI=1.16-1.52, P<0.01). In subgroup analysis, statistically elevated cancer risk was found in both Asian and Caucasian populations (for Asian, AA+AG vs. GG: OR=1.74, 95% CI=1.22-2.47, P<0.01; for Caucasian, AA+AG vs. GG: OR=1.24, 95% CI=1.09-1.42, P<0.01). Our result indicated that CXCL12 G801A polymorphism is a risk factor for cancer. To validate the finding, further large-size case-control studies are warranted.
